Mycophenolate mofetil in pediatric renal transplantation

Transplantation

Volumn 80, Issue SUPPL. 2, 2005, Pages

  Ettenger, Robert ^a,c   Sarwal, Minnie M ^b  

^a MATTEL CHILDREN S HOSPITAL   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

Mycophenolate mofetil; Mycophenolic acid; Pediatrics; Renal transplantation; Therapeutic drug monitoring

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; ERYTHROPOIETIN; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; BONE DISEASE; BONE MARROW SUPPRESSION; CATARACT; CLINICAL TRIAL; CUSHINGOID SYNDROME; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GLOMERULOSCLEROSIS; GLUCOSE INTOLERANCE; GRAFT FAILURE; GRAFT SURVIVAL; GROWTH RETARDATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHOPROLIFERATIVE DISEASE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PEDIATRICS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; VIRUS INFECTION;

CHILD; CLINICAL TRIALS; CYCLOSPORINE; DRUG MONITORING; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MULTICENTER STUDIES; MYCOPHENOLIC ACID; PREDNISONE; TREATMENT OUTCOME;

EID: 27644524478     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000186957.32801.c0     Document Type: Review

References (58)

1. Allison AC, Eugui EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol 1993; 14: 353.
2. Allison AC, Eugui EM. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc 1994; 26: 3205.
3. NAPRTCS AR. North American Pediatric Renal Transplant Cooperative Study. Available at: http://spitfire.emmes.com/study/ped/resources/annlrept2004.pdf 2004. Accessed June 15, 2005.
4. Evans HM, McKiernan PJ, Kelly DA. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation 2005; 79: 1575.
5. Sarwal MM, Yorgin PD, Alexander S, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001; 72: 13.
6. Chabria D, Weintraub RG, Kilpatrick NM. Mechanisms and management of gingival overgrowth in paediatric transplant recipients: a review. Int J Paediatr Dent 2003; 13: 220.
7. Kari JA, Trompeter RS. What is the calcineurin inhibitor of choice for pediatric renal transplantation? Pediatr Transplant 2004; 8: 437.
8. Dobbels F, Van Damme-Lombaert R, Vanhaecke J, De Geest S. Growing pains: non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatr Transplant 2005; 9: 381.
9. Chao AB, Shah S, Salvatierra O, Sarwal MM. Extended analysis of steroid-free immunosuppression supports study safety and efficacy [Abstract]. Am J Transplant 2005; 5 (Suppl 11): 402.
10. Ettenger R, Warshaw B, Mentser M, et al. Mycophenolate Mofetil (MMF) in pediatric renal transplantation. Pediatr Nephrol 1996; 10: C39.
11. Ettenger R, Mentser M, Warshaw B, et al. The long-term use of mycophenolate mofetil in pediatric renal transplantation: a report of the Pediatric Mycophenolate Mofetil Study Group (PMMSG). Transplantation 1999; 67: S124.
12. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225.
13. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
14. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321.
15. Ettenger R, Cohen A, Nast C, et al. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation. Transplant Proc 1997; 29: 340.
16. Benfield MR, Symons JM, Bynon S, et al. Mycophenolate mofetil in pediatric renal transplantation. Pediatr Transplant 1999; 3: 33.
17. Bunchman T, Navarro M, Broyer M, et al. The use of mycophenolate mofetil suspension in pediatric renal allograft recipients. Pediatr Nephrol 2001; 16: 978.
18. Hoecker B, Webert L, Bunchman T, et al. Mycophenolate mofetil suspension in pediatric renal transplantation: 3-year data from the Tricontinental Trial. [Abstract]. Am J Transplant 2005; 5 (Suppl 11): 494.
19. Staskewitz A, Kirste G, Tonshoff B, et al. Mycophenolate mofetil in pediatric renal transplantation without induction therapy: results after 12 months of treatment. German Pediatric Renal Transplantation Study Group. Transplantation 2001; 71: 638.
20. Jungraithmayr T, Staskewitz A, Kirste G, et al. Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years. Transplantation 2003; 75: 454.
21. Cransberg K, Marlies Cornelissen EA, Davin JC, et al. Improved outcome of pediatric kidney transplantations in the Netherlands-effect of the introduction of mycophenolate mofetil? Pediatr Transplant 2005; 9: 104.
22. Ferraris JR, Ghezzi LF, Vallejo G, et al. Improved long-term allograft function in pediatric renal transplantation with mycophenolate mofetil. Pediatr Transplant 2005; 9: 178.
23. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
24. Henne T, Latta K, Strehlau J, et al. Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Transplantation 2003; 76: 1326.
25. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1998; 9: 1511.
26. Weber LT, Schutz E, Lamersdorf T, et al. Therapeutic drug monitoring of total and free mycophenolic acid (MPA) and limited sampling strategy for determination of MPA-AUC in paediatric renal transplant recipients. The German Study Group on Mycophenolate Mofetil (MMF) Therapy. Nephrol Dial Transplant 1999; 14 (Suppl 4): 34.
27. Weber LT, Schutz E, Lamersdorf T, et al. Pharmacokinetics of mycophenolic cid (MPA) and free MPA in paediatric renal transplant recipients - a multicentre study. The German Study Group on Mycophenolate Mofetil (MMF) Therapy. Nephrol Dial Transplant 1999; 14 (Suppl 4): 33.
28. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the German Study Group on Mycophenolate Mofetil Therapy. J Am Soc Nephrol 2002; 13: 759.
29. Weber L, Hoecker B, Bunchman T, et al. Long-term pharmacokinetics of mycophenolate mofetil (MMF) suspension in pediatric renal transplant recipients: 3-year results from the prospective tricontinental trial. [Abstract]. Am J Transplant 2005; 5 (Suppl 11): 402.
30. Shaw LM, Mick R, Nowak I, et al. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol 1998; 38: 268.
31. Atcheson BA, Taylor PJ, Kirkpatrick CM, et al. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit 2004; 26: 284.
32. Filler G, Lepage N. To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription? Pediatr Nephrol 2004; 19: 962.
33. Gajarski RJ, Crowley DC, Zamberlan MC, Lake KD. Lack of correlation between MMF dose and MPA level in pediatric and young adult cardiac transplant patients: Does the MPA level matter? Am J Transplant 2004; 4: 1495.
34. Pape L, Ehrich JH, Offner G. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function. Clin Transplant 2004; 18: 576.
35. David-Neto E, Montiero Pereira Araujo L, Sumita NM, et al. Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. Pediatr Nephrol 2003; 18: 266.
36. Filler G. Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy. Transpl Int 2004; 17: 120.
37. Payen S, Zhang D, Maisin A, et al. Population Pharmacokinetics of Mycophenolic Acid in Kidney Transplant Pediatric and Adolescent Patients. Ther Drug Monit 2005; 27: 378.
38. Weber LT, Shipkova M, Armstrong VW, et al. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem 2002; 48: 517.
39. Filler G, Lampe D, Mai I, et al. Dosing of MMF in combination with tacrolimus for steroid-resistant vascular rejection in pediatric renal allografts. Transpl Int 1998; 11 (Suppl 1): S82.
40. Smak Gregoor PJ, van Gelder T, Hesse CJ, et al. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant 1999; 14: 706.
41. Pou L, Brunet M, Cantarell C, et al. Mycophenolic acid plasma concentrations: influence of comedication. Ther Drug Monit 2001; 23: 35.
42. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119.
43. Filler G, Foster J, Berard R, et al. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. Transplant Proc 2004; 36: 1327.
44. Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002; 62: 1060.
45. Schwartz J, Ishitani M, Weckwerth J, et al. Decreased incidence of rejection in pediatric kidney recipients using thymoglobulin induction and triple immunosuppression with tacrolimus MMF, and prednisone. [Abstract]. Am J Transplant 2005; 5 (Suppl 11): 184.
46. Hoecker B, Feneberg R, Koepf S, et al. Switch of immunosuppression from calcineurin inhibitors (CNI) to sirolimus (SRL) in pediatric renal transplant recipients with CNI toxicity. [Abstract]. Am J Transplant 2005; 5 (Suppl 11): 494.
47. David-Neto E, Araujo LM, Lemos FC, et al. Introduction of mycophenolate mofetil and cyclosporin reduction in children with chronic transplant nephropathy. Pediatr Transplant 2001; 5: 302.
48. Filler G, Gellermann J, Zimmering M, Mai I. Effect of adding Mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity. Transpl Int 2000; 13: 201.
49. Hocker B, John U, Plank C, et al. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years. Transplantation 2004; 78: 228.
50. Sarwal MM, Vidhun JR, Alexander SR, et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003; 76: 1331.
51. John E, Lumpaopang A, Oberholzer J, et al. Superior out-comes in growth and renal function with early steroid discontinuation in pediatric kidney transplantation: 11/2 years follow up. [Abstract]. Am J Transplant 2005; 5 (Suppl 11): 494.
52. Bhakta N, Rianthavorn P, Gjertson D, et al. Is steroid free immunosuppression safe for the pediatric renal transplant patient: A case control study. [Abstract]. Am J Transplant 2005; 5 (Suppl 11): 494.
53. Vidhun JR, Sarwal MM. Corticosteroid avoidance in pediatric renal transplantation. Pediatr Nephrol 2005; 20: 418.
54. Benfield MR, Munoz R, Warshaw B. A randomized controlled double-blind trial of steroid withdrawal in pediatric renal transplantation: a Study of the Cooperative Clinical Trials in Pediatric Transplantation (CCTPT). [Abstract]. Am J Transplant 2005; 5 (Suppl 11): 402.
55. McDonald R, McIntosh M, Stablein D, et al. Increased incidence of PTLD in pediatric renal transplant recipients enrolled in a randomized controlled trial of steroid withdrawal: a study of the CCTPT. [Abstract]. Am J Transplant 2005; 5 (Suppl 11): 418.
56. Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 1289.
57. Dharnidharka VR, Sullivan EK, Stablein DM, et al. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 71: 1065.
58. Dharnidharka VR, Ho PL, Stablein DM, et al. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2002; 6: 396.